These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31703609)

  • 1. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
    Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
    J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
    Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
    J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1
    D'Angelo SP; Melchiori L; Merchant MS; Bernstein D; Glod J; Kaplan R; Grupp S; Tap WD; Chagin K; Binder GK; Basu S; Lowther DE; Wang R; Bath N; Tipping A; Betts G; Ramachandran I; Navenot JM; Zhang H; Wells DK; Van Winkle E; Kari G; Trivedi T; Holdich T; Pandite L; Amado R; Mackall CL
    Cancer Discov; 2018 Aug; 8(8):944-957. PubMed ID: 29891538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
    Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
    Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
    Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
    J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
    Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
    Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of engineered T-cell therapy for synovial sarcoma.
    Dallos M; Tap WD; D'Angelo SP
    Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
    Poncette L; Chen X; Lorenz FK; Blankenstein T
    J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
    Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
    Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
    Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
    Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!
    Keung EZ; Tawbi HA
    Cancer Discov; 2018 Aug; 8(8):914-917. PubMed ID: 30076141
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
    Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA
    J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
    Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
    J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination.
    Vita R; Guarneri F; Agah R; Benvenga S
    Thyroid; 2014 Feb; 24(2):390-4. PubMed ID: 23590991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
    Kawai A; Ishihara M; Nakamura T; Kitano S; Iwata S; Takada K; Emori M; Kato K; Endo M; Matsumoto Y; Kakunaga S; Sato E; Miyahara Y; Morino K; Tanaka S; Takahashi S; Matsuo F; Matsumine A; Kageyama S; Ueda T
    Clin Cancer Res; 2023 Dec; 29(24):5069-5078. PubMed ID: 37792433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
    Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.